xevinapant (Debio 1143)
Selected Solid Tumors
Debio 1143 is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins) that displays immunomodulatory properties making it a natural candidate for combination with Immune Checkpoint Inhibitors. In addition, like other members of the class, Debio 1143 promotes apoptosis of cancer cells by mimicking the activity of the natural Second Mitochondrial-derived Activator of Caspases (SMAC). Through this dual mode of action, Debio 1143 is expected to improve cancer patient treatment outcomes in combination with immunotherapy, chemotherapy and/or radiotherapy respectively investigated in NSCLC, H&N cancer and Ovarian Cancer.
SMARTPLUS Trial information
SMARTPLUS-106 is a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in the following indications:Gastrointestinal cancers, Gynecologic cancers, Small cell lung cancers and Head & neck cancers
Small cell lung cancer
May 21, 2019
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial